Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalEDTXF -2.10%7 Earnings per Share (Diluted) is $-0.09 as of Jun. 2026. GuruFocus rates EDTXF with a GF Score™ of 7/100 and a GF Value™ of $0.58 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 75% on this metric.
Spectral Medical's EPS (Basic) for the
three
months ended in Jun. 2026 was $0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.09.
During the past 3 years, the average EPS without NRIGrowth Rate was -6.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -5.20% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -4.40% per year.
During the past 13 years, Spectral Medical's highest 3-Year average EPS without NRI Growth Rate was 46.90% per year. The lowest was -49.40% per year. And the median was 9.80% per year.
Spectral Medical (OTCPK:EDTXF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Spectral Medical Earnings per Share (Diluted) Related Terms
Spectral Medical Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Spectral Medical's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical Earnings per Share (Diluted) Chart
EDTXF vs TMO, DHR, NTRA: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Spectral Medical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's PE Ratio distribution charts can be found below:
* The bar in red indicates where Spectral Medical's PE Ratio falls into.
Spectral Medical Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Spectral Medical's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.09 mean?
Spectral Medical (EDTXF) has a Earnings per Share (Diluted) of $-0.09 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Spectral Medical and its competitors. According to the industry distribution chart, Spectral Medical ranks #120 out of 160 companies in the Medical Diagnostics & Research industry, placing it in the top 75%.
Is Spectral Medical's Earnings per Share (Diluted) too high?
Spectral Medical's current Earnings per Share (Diluted) is $-0.09. Based on the distribution chart, Spectral Medical ranks #120 out of 160 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Spectral Medical has a GF Score™ of 7/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Earnings per Share (Diluted) compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #120 out of 160 companies for Earnings per Share (Diluted). This places Spectral Medical in the lower half of its industry. The industry median Earnings per Share (Diluted) is 11.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 11.10, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Spectral Medical and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current Earnings per Share (Diluted) is $-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (EDTXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.58, compared to a current price of $0.90 — trading 56% above its estimated fair value. The current Earnings per Share (Diluted) is $-0.09. Spectral Medical's overall GF Score™ is 7/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Spectral Medical (EDTXF), the current Earnings per Share (Diluted) is $-0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (EDTXF) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of $0.90 is trading 56% above its estimated GF Value™ of $0.58.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for EDTXF:
Earnings per Share (Diluted): $-0.09
GF Value™: $0.58 vs. price of $0.90 (56% above fair value)
No single metric tells the full story. See the EDTXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
7GF Score
Get the complete analysis for EDTXF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDTXF has been successfully added to your 
